Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (9247)	10/1/2003 4:44:32 PM
From: tuck	Respond to of 52153

Vaguely on point, but mainly referenced because it seems generally important . . . "Functional genomics of cell morphology using RNA interference: pick your style, broad or deep" While this talks about screening with RNAI, it contains a couple of notes of interest to most followers of biotech. One is the alarming number of alternative pathways, which is good if you have them, and bad if some invading pathogen has them. Of course, both are true, with implications for anti-cancer and antiviral drugs, among others. The second is a call for standardization of names of genes. I agree with the author that that is long overdue. jbiol.com Registration is now required for the Journal of Biology, but it remains open access. Cheers, Tuck